{"groups":[{"description":"Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.\n\nziv-aflibercept: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"FG000","title":"Arm I"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}